Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin–piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia

Table 2 Treatment outcome from Papua TES during the 42 day of follow-up

Classification of treatment outcome	Papua
	Microscopy result (without PCR correction)		With PCR correction
	n	% (95% CI)^a	n	% (95% CI)^a
Total patient’s treatment failure and completed the 42 day-follow-up
Treatment failure
ETF	0	0% (0.0–3.1)	0	0% (0.0–3.4)
LCF	0	0% (0.0–3.1)	0	0% (0.0–3.4)
LPF	10	8.5% (4.2–15.2)	1	0.9% (0.0–5.1)
ACPR	107	91.5% (84.8–95.8)	107	99.1% (94.9–100.0)
Patient LFU/WTH	25	–	34	–
Total patients at baseline	142	–	142	–

ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, LFU lost to follow up, WTH withdrawn
^aKaplan–Meier analysis

ISSN: 1475-2875